The short answer is this: mental health screening is part of safe medical cannabis prescribing. It is not a character test, and it is not something to game.
The wider point is contraindications, cautions and risk factors. Mental health is one of the big ones, but it is not the only one. A prescriber needs to understand the full risk picture before deciding whether a cannabis-based medicinal product is appropriate. That includes your physical health, immune system, medicines, previous treatments, and mental health history. It also includes any past reactions to cannabis, whether prescribed or not.
This matters because medical cannabis can affect mood, behaviour, thinking, alertness, and perception. The NHS lists possible side effects including behavioural or mood change, feeling high, hallucinations, and suicidal thoughts. It also notes potential psychosis risk with THC-containing cannabis products, especially where exposure is higher.
If you are having hallucinations, new suicidal thoughts, severe mood changes, or you do not feel able to keep yourself or someone else safe, do not treat this as a normal article-reading problem. Use NHS urgent help routes. NHS advice is to use 111 or ask for an urgent GP appointment for urgent mental-health help, and to call 999 or go to A&E if life is at risk or someone cannot be kept safe.
This article is general information. It cannot diagnose you, decide suitability, or replace the clinician responsible for assessing whether medical cannabis is appropriate for you. For the site boundary, see the MCPH medical disclaimer and editorial policy.
Why mental health screening happens
Medical cannabis is not just a lifestyle product with a prescription label attached. In UK clinical language, these are cannabis-based medicinal products. Some are licensed for specific uses, and many are unlicensed medicines when prescribed outside those narrow licensed settings.
That raises the safety bar. NICE guidance puts cannabis-based medicinal products inside specialist-led prescribing, monitoring, shared decision making, and adverse-effect recording. CQC guidance also treats unlicensed CBPMs as higher-risk medicines because they may not have been assessed for safety, quality, and efficacy in the same way as licensed medicines.
In normal language: the prescriber needs to know whether the possible benefit is worth the risk for you, not for an imaginary average patient.
Mental health is part of that. A clinician may need to know whether you have current symptoms, previous serious episodes, crisis support, psychiatric care, medicines that affect the central nervous system, or a history of becoming anxious, paranoid, unusually low, unusually elevated, confused, or detached from reality after cannabis use.
But the screening conversation can be wider than mental health. Some risks are psychiatric. Some are physical. Some are about other medicines. Some are about the form of medical cannabis being considered. For example, a patient who is immunosuppressed or taking immunosuppressant medicines may need a different product-safety conversation from someone without that risk. Dried flower has microbial-safety considerations, and irradiation is one method used to reduce microorganisms in cannabis flower. That does not mean MCPH can decide which product is right. It means the prescriber needs to know the relevant risks before discussing options such as flower, oil, irradiated flower or non-irradiated flower.
The point is not to punish honesty. The point is that a safe decision depends on the truth.
What a prescriber may ask about
The exact assessment belongs to the clinician, not MCPH. But for a safety conversation, it is reasonable to expect questions around:
- Current mental-health symptoms or recent changes.
- Past episodes involving hallucinations, delusions, mania, severe depression, self-harm, or suicidal thoughts.
- Any diagnosis or care from a GP, psychiatrist, community mental-health team, crisis team, or talking-therapy service.
- Current and recent medicines, including antidepressants, antipsychotics, sedatives, antiepileptic medicines, pain medicines, immunosuppressants, and medicines that make you drowsy.
- Physical-health factors that could change the risk discussion, such as immune-system problems, significant infection risk, liver or kidney issues, cardiovascular concerns, pregnancy or breastfeeding, or complex long-term conditions.
- Alcohol or non-prescribed drug use, including non-prescribed cannabis.
- Previous experience with cannabis, including anxiety, panic, paranoia, hallucinations, or feeling out of control.
- Product-form issues that may need clinician judgement, such as whether flower, oil, extract, irradiated flower or non-irradiated flower is appropriate.
- Whether someone at home or in your care network would notice if your mental state changed.
That is not a list of reasons you will automatically be refused. It is a list of facts that can change the risk assessment.
A past mental-health problem does not create one universal answer. For one person, it may mean extra caution, closer monitoring, or more information from existing records. For another, it may mean the prescriber decides medical cannabis is not appropriate. The honest answer is that it depends on the full clinical picture.
What not to hide
If you already use cannabis, say so. If cannabis has ever made you feel paranoid, panicky, detached, unusually low, unusually elevated, or unlike yourself, say so. If you have ever heard or seen things other people could not, believed things that later turned out not to be true, or been told you may have had psychosis, say so.
That may feel uncomfortable, but it is useful information. A prescriber cannot manage a risk they do not know about.
The same applies to suicidal thoughts, self-harm, severe depression, bipolar disorder, psychosis, PTSD, anxiety, substance-use problems, or any recent crisis-team or hospital contact. It also applies to immunosuppressant medicines, immune-system conditions, complex physical diagnoses, previous serious infections, pregnancy or breastfeeding, and anything else a clinician has told you changes medicine risk. MCPH cannot tell you how those details should affect a prescribing decision. The safe line is simpler: disclose them and let the appropriate clinician make the call.
If symptoms change after starting treatment
The NHS medical cannabis page says side effects should be reported to the medical team. That is the practical rule to keep hold of.
Contact the prescribing team promptly if you notice new or worsening symptoms such as:
- Hallucinations.
- Suicidal thoughts.
- Severe anxiety, panic, or paranoia.
- Marked mood or behaviour changes.
- Confusion, unusual agitation, or feeling out of control.
- Feeling so drowsy, impaired, or unlike yourself that normal activities no longer feel safe.
This is not about trying to work out by yourself whether the medicine caused it. It is about making sure the people responsible for your care know what has changed.
If there is immediate danger, use urgent help. NHS advice is clear that a mental-health emergency should be taken as seriously as a physical one. Use 999 or A&E where life is at risk or someone cannot be kept safe.
What to prepare before a screening conversation
You do not need to turn the appointment into a legal case file. The useful version is more practical.
Bring or prepare:
- A current list of medicines and supplements, including medicines that affect mood, sleep, pain, seizures, immunity or infection risk.
- A short note of relevant mental-health history, especially serious episodes, hospital care, crisis support, or psychiatric care.
- Any known diagnoses or current support arrangements.
- Relevant physical-health risks, including immune-system issues, immunosuppressant medicines, liver or kidney issues, cardiovascular concerns, pregnancy or breastfeeding, or complex long-term conditions.
- A clear account of previous cannabis use and any bad reactions, including self-medication.
- Your Summary Care Record or relevant notes if the clinic asks for records.
- Questions you want to ask the prescriber, especially about risks, interactions, monitoring, product form, and what to do if symptoms change.
Try not to present the neatest possible version of yourself. Present the accurate one.
Where this sits in the wider UK pathway
If you are still working out how the UK process fits together, start with MCPH’s guide to how the medical cannabis prescription process works in the UK. If you are checking whether you may qualify at all, read Medical Cannabis Qualifying Conditions.
Those pages explain access and suitability in broader terms. This page is narrower. It is about mental-health risk, screening, and the safety conversation.
Bottom line
Mental health screening is there because medical cannabis can affect the mind as well as the body. Wider screening is there because medical cannabis is still prescribed inside a real medical system, not a one-size-fits-all route. For some patients, the conversation may be straightforward. For others, contraindications, cautions, product suitability, immune-system risks, medicine interactions or psychiatric history may be the most important part of the assessment.
The best thing you can do is not to guess what the prescriber wants to hear. Be clear about your history, current symptoms, medicines, physical-health risks, previous cannabis use, self-medication, and any worrying changes. There is a long history of people using cannabis outside the prescription system, including people with complex mental or physical health histories. That does not mean a UK clinician will decide prescribed medical cannabis is right for that patient under this medical system. Honesty gives the prescriber the best chance of building a safe treatment plan, or saying when the risk is too high. If there is urgent risk, use NHS urgent support rather than waiting for a routine appointment.
Useful, not shiny. The safe version is honest information, proper clinical judgement, and no pretending a blog article can make the decision for you.
More from the MCPH Patient Guide
Use the MCPH Patient Guide to follow the UK medical cannabis pathway in order, from eligibility and records through to safety, side effects and review questions.
Sources
- NHS: Medical cannabis – https://www.nhs.uk/medicines/medical-cannabis/
- NICE NG144: Cannabis-based medicinal products recommendations – https://www.nice.org.uk/guidance/ng144/chapter/Recommendations
- NHS England: Cannabis-based products for medicinal use – https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC: Information for doctors on cannabis-based products for medicinal use – https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- CQC: Cannabis-based medicinal products, what CQC expects from providers – https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
- NHS: Where to get urgent help for mental health – https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/
- NHS: Psychosis overview – https://www.nhs.uk/mental-health/conditions/psychosis/overview/
